Mitsubishi UFJ Asset Management Co. Ltd. Sells 879 Shares of Illumina, Inc. (NASDAQ:ILMN)

Mitsubishi UFJ Asset Management Co. Ltd. lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 114,179 shares of the life sciences company’s stock after selling 879 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.07% of Illumina worth $15,529,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Golden State Wealth Management LLC purchased a new stake in Illumina during the 4th quarter valued at $32,000. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the fourth quarter worth about $45,000. Assetmark Inc. raised its position in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. purchased a new stake in Illumina in the 4th quarter worth approximately $48,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Down 0.8 %

Illumina stock opened at $79.34 on Tuesday. The firm has a market cap of $12.57 billion, a price-to-earnings ratio of -10.33, a PEG ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $77.54 and a 12 month high of $156.66. The stock has a fifty day simple moving average of $101.65 and a two-hundred day simple moving average of $126.49.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ILMN. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and reduced their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Stephens restated an “overweight” rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. Finally, Barclays reaffirmed an “underweight” rating on shares of Illumina in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.